UBS Group Increases Cryoport (NASDAQ:CYRX) Price Target to $11.00

Cryoport (NASDAQ:CYRX) had its price target raised by UBS Group from $10.00 to $11.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Cryoport in a research note on Monday. Guggenheim started coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.83.

Cryoport Trading Down 11.7 %

NASDAQ CYRX opened at $5.44 on Tuesday. The stock has a market cap of $271.51 million, a P/E ratio of -1.61 and a beta of 1.67. Cryoport has a fifty-two week low of $4.58 and a fifty-two week high of $20.11. The stock has a 50 day simple moving average of $6.50 and a two-hundred day simple moving average of $7.26. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The business had revenue of $59.53 million during the quarter, compared to analysts’ expectations of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period in the previous year, the business earned ($0.29) EPS. On average, analysts forecast that Cryoport will post -0.99 earnings per share for the current year.

Insider Transactions at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 19,830 shares of company stock valued at $118,353 in the last three months. 10.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CYRX. Franklin Resources Inc. grew its stake in shares of Cryoport by 0.4% in the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock worth $3,012,000 after acquiring an additional 1,512 shares during the last quarter. Rhumbline Advisers increased its stake in Cryoport by 2.9% during the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock valued at $492,000 after purchasing an additional 1,764 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its holdings in Cryoport by 148.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after buying an additional 2,120 shares during the last quarter. Nebula Research & Development LLC raised its holdings in Cryoport by 21.6% in the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock worth $97,000 after buying an additional 2,207 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Cryoport by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after buying an additional 2,226 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.